~~<i id='3BCA4D3B34'><strike id='3BCA4D3B34'><tt id='3BCA4D3B34'><pre id='3BCA4D3B34'></pre></tt></strike></i>~~

Home» leisure time» entertainment

entertainment

author：explore 2025-09-28 22:43:16 Page View：16

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bernie brings in new pharma CEOs to talk drug prices
Next article： Alkermes shareholders re

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Faced with fears of OxyContin misuse, sales reps touted its safety

Photoillustration:STAT;photo:GettyImagesPIKEVILLE,Ky.—AyearandahalfaftertheopioidpainkillerOxyContin

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Timeline: Special counsel's investigation into Trump's handling of classified documents

7:06ThisimagecontainedinacourtfilingbytheDepartmentofJusticeonAug.30,2022,andpartiallyredactedbythes

WSS

entertainment

entertainment

comprehensive

explore

Timeline: Special counsel's investigation into Trump's handling of classified documents